NCT06068881 2026-01-30
Mandolin
Ipsen
Phase 2 Withdrawn
Clinical Trials
5 trialsNCT06575686 2026-01-21
Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
City of Hope Medical Center
Phase 2 Suspended
NCT05994235 2025-04-09
Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma
Weill Medical College of Cornell University
Phase 2 Recruiting
NCT04762160 2024-03-25
SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
Ipsen
Phase 2 Terminated
NCT03456726 2022-12-16
Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation
Eisai Inc.
Phase 2 Completed